For this purpose, our goal was to investigate the potential therapeutic value of EPO against TAA-induced hepatic fibrosis by concentrating on TLR4 and PI3K/Akt signaling pathway modification. The gene discussed is TLR4; the disease is Hepatic fibrosis.